Ikarian Capital, LLC Otonomy, Inc. Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.72 - $2.51 $375,575 - $548,078	-218,358 Reduced 99.92%	180 $0
Q1 2022 May 13, 2022	BUY	$1.72 - $2.47 $17,599 - $25,273	10,232 Added 4.91%	218,538 $525,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $3,861 - $6,963	-3,165 Reduced 1.5%	208,306 $399,000
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $435,630 - $564,627	211,471 New	211,471 $472,000
Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $645,749 - $1.62 Million	-259,337 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$3.48 - $6.47 $610,562 - $1.14 Million	-175,449 Reduced 40.35%	259,337 $1.68 Million
Q3 2020 Nov 16, 2020	SELL	$3.16 - $4.36 $2 Million - $2.76 Million	-632,485 Reduced 59.26%	434,786 $1.76 Million
Q2 2020 Aug 14, 2020	SELL	$1.87 - $3.84 $561,000 - $1.15 Million	-300,000 Reduced 21.94%	1,067,271 $3.86 Million
Q1 2020 May 15, 2020	BUY	$1.58 - $4.06 $474,000 - $1.22 Million	300,000 Added 28.11%	1,367,271 $2.69 Million
Q4 2019 Jan 31, 2020	BUY	$2.13 - $3.83 $2.27 Million - $4.09 Million	1,067,271 New	1,067,271 $4.09 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.